Role of Amyloid-β and Tau Proteins in Alzheimer’s Disease: Confuting the Amyloid Cascade
Open accessThe DOI matches its Crossref record; 223 of the 223 references it cites were found in a registry or an index.
Abstract
The "Amyloid Cascade Hypothesis" has dominated the Alzheimer's disease (AD) field in the last 25 years. It posits that the increase of amyloid-β (Aβ) is the key event in AD that triggers tau pathology followed by neuronal death and eventually, the disease. However, therapeutic approaches aimed at decreasing Aβ levels have so far failed, and tau-based clinical trials have not yet produced positive findings. This begs the question of whether the hypothesis is correct. Here we have examined literature on the role of Aβ and tau in synaptic dysfunction, memory loss, and seeding and spreading of AD, highlighting important parallelisms between the two proteins in all of these phenomena. We discuss novel findings showing binding of both Aβ and tau oligomers to amyloid-β protein precursor (AβPP), and the requirement for the presence of this protein for both Aβ and tau to enter neurons and induce abnormal synaptic function and memory. Most importantly, we propose a novel view of AD pathogenesis in which extracellular oligomers of Aβ and tau act in parallel and upstream of AβPP. Such a view will call for a reconsideration of therapeutic approaches directed against Aβ and tau, paving the way to an increased interest toward AβPP, both for understanding the pathogenesis of the disease and elaborating new therapeutic strategies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TRx0237 (21, LMTX) is a tau aggregation inhibitor.465”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [465]
Citations
Cites
Items 201–223 of 223
Cross Currents in Protein Misfolding Disorders: Interactions and Therapy
Morales, R., Green, K., & Soto, C. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789541998 · Cited by 72 · cited 1×
“This phenomenon is defined as seeding [161, 183] and can be distinguished as homologous or heterologous [183, 187], While homologous seeding involves monomers of the same type, heterologous seeding or cross-seeding takes place when a nucleus formed by a certain misfolded protein promotes polymerization of a different…”
Selective vulnerability in Alzheimer's disease: Amyloid precursor protein and p75NTR interaction
Fombonne, J., Rabizadeh, S., Banwait, S., Mehlen, P., & Bredesen, D. E. (2009) · Annals of Neurology · doi:10.1002/ana.21578 · Cited by 69
Effects of different amyloid β-protein analogues on synaptic function
Ripoli, C., Piacentini, R., Riccardi, E., Leone, L., Puma, D. D. L., Bitan, G., & Grassi, C. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.06.027 · Cited by 67
Self-citationShin, R., Ogino, K., Shimabuku, A., Taki, T., Nakashima, H., Ishihara, T., & Kitamoto, T. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0211-z · Cited by 67
A New Approach to Follow a Single Extracellular Vesicle—Cell Interaction using Optical Tweezers
Prada, I., Amin, L., Furlan, R., Legname, G., Verderio, C., & Cojoc, D. (2016) · BioTechniques · doi:10.2144/000114371 · Cited by 65
Koppensteiner, P., Trinchese, F., Fà, M., Puzzo, D., Gulisano, W., Yan, S., Poussin, A., Liu, S., Orozco, I., Dale, E., et al. (2016) · Scientific Reports · doi:10.1038/srep32553 · Cited by 65 · cited 1×
“Finally, even A (cid:2) concentration per se has become a relative concept, as the persistence of a low picomolar A (cid:2) concentration in [39].”
Self-citationLawrence, J. L. M., Tong, M., Alfulaij, N., Sherrin, T., Contarino, M., White, M. M., Bellinger, F. P., Todorovic, C., & Nichols, R. A. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0326-14.2014 · Cited by 60
Stabilization of dynamic microtubules by mDia1 drives Tau-dependent Aβ1–42 synaptotoxicity
Qu, X., Yuan, F. N., Corona, C., Pasini, S., Pero, M. E., Gundersen, G. G., Shelanski, M. L., & Bartolini, F. (2017) · Journal of Cell Biology · doi:10.1083/jcb.201701045 · Cited by 59 · cited 2×
“Interestingly, recent work has demonstrated that A (cid:2) acutely induces tubulin post-translational modifications and stabilizes dynamic microtubules promoting tau-dependent loss of dendritic spines and tau hyperphosphorylation [52].”
Amyloid-beta isoform metabolism quantitation by stable isotope-labeled kinetics
Mawuenyega, K. G., Kasten, T., Sigurdson, W., & Bateman, R. J. (2013) · Analytical Biochemistry · doi:10.1016/j.ab.2013.04.031 · Cited by 58 · cited 1×
“, Aβ15, Aβ16, and Aβ17, have been also detected [6].”
Nicholls, R. E., Sontag, J.-M., Zhang, H., Staniszewski, A., Yan, S., Kim, C. Y., Yim, M., Woodruff, C. M., Arning, E., Wasek, B., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521018113 · Cited by 56 · cited 1×
“…shown that overexpression of the protein phosphatase 2A (PP2A) methyltransferase, leucine carboxyl methyltransferase-1, leads to a decrease in A (cid:2) PP phosphorylation at the PP2A-sensitive Thr-668 site and protects mice against A (cid:2) -induced damage of synaptic plasticity and memory [219].”
Self-citationFraser, S. P., Suh, Y. H., Chong, Y. H., & Djamgoz, M. B. A. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66052034.x · Cited by 48
Yamamoto, M., Ozawa, H., Saito, T., Hatta, S., Riederer, P. F., & Takahata, N. (1997) · Journal of Neural Transmission · doi:10.1007/bf01291889 · Cited by 46 · cited 1×
“Interestingly, these findings were validated in humans affected by AD showing a decrease in CREB and phospho-CREB levels in hippocampus [118–122].”
Giaccone, G., Pedrotti, B., Migheli, A., Verga, L., Perez, J., Racagni, G., Smith, M. A., Perry, G. L., GIOIA, L. D., Selvaggini, C., et al. (1996) · Europe PMC (PubMed Central) · Cited by 44
Islam, K., & Levy, E. (1997) · Europe PMC (PubMed Central) · Cited by 40
Reduced immunoreactivity of adenylyl cyclase in dementia of the Alzheimer type
Yamamoto, M., Ozawa, H., Saito, T., Frölich, L., Riederer, P. F., & Takahata, N. (1996) · Neuroreport · doi:10.1097/00001756-199611250-00033 · Cited by 39
Oka, M., Fujisaki, N., Maruko-Otake, A., Ohtake, Y., Shimizu, S., Saito, T., Hisanaga, S.-I., Iijima, K. M., & Ando, K. (2017) · The Journal of Biochemistry · doi:10.1093/jb/mvx038 · Cited by 39 · cited 6×
“A (cid:2) and tau also target other molecules upstream of CREB, among which the Ca 2 + /calmodulin-dependent protein kinase II (CaMKII), another key molecule needed for LTP and memory formation [123].”
InfluentialLombino, F., Biundo, F., Tamayev, R., Arancio, O., & D’Adamio, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057120 · Cited by 32 · cited 2×
“…sites for intracellular proteins that interact with A (cid:2) PP, is increased in AD cases [216] and knock-in mouse bearing a Thr(668)Ala mutation preventing phosphorylation at this site protects against abnormal synaptic plasticity and memory when crossed with a mouse model of dementia [217].”
Self-citationSome evolutionary perspectives on Alzheimer's disease pathogenesis and pathology
Glass, D. J., & Arnold, S. E. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2408 · Cited by 29 · cited 1×
“Inconclusion Inconclusion,takinginto accountalmostonecenturyofresearch,itemerges thattheA (cid:2) model of AD is insufficient [40, 41] and needs to be reconsidered [34].”
Cardona-Go´mez, G. P., Arango-Davila, C., Gallego-Go´mez, J. C., Barrera-Ocampo, A., Pimienta, H., & Garcia-Segura, L. M. (2006) · NeuroReport · doi:10.1097/01.wnr.0000230508.78467.96 · Cited by 25 · cited 1×
“The flanking region of MBD contains the majority of phosphate acceptor residues, and the phosphorylation of these sites is relevant for regulating microtubule polymerization [63–66], regulation of axonal transport [67] and neurotransmitter receptors [68, 69], interference with vesicles trafficking [70] and apolipoprot…”
Spreading of Pathology in Alzheimer’s Disease
Lv, Z., Tan, C., Yu, J., & Tan, L. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9765-2 · Cited by 18 · cited 3×
“However, whether the mechanism underlying tau propagation is mediated by TNTs, non-vesicular direct translocation or through secretory lysosomes into extracellular space [106, 162, 181, 182] is still under investigation.”
The Involvement of NR2B and tau Protein in MG132-Induced CREB Dephosphorylation
Xie, M., Li, Y., Wang, S., Yu, Q., Meng, X., & Liao, X. (2017) · Journal of Molecular Neuroscience · doi:10.1007/s12031-017-0919-8 · Cited by 12 · cited 1×
“Tau overexpression and hyperphosphorylation was also found to be accompanied by a reduction of CREB phosphorylation at Ser133, mediated by a decrease of phosphorylation of NR2B (Tyr1472) [116].”
BackgroundMechanism of Alzheimer Amyloid β-Protein Precursor Localization to Membrane Lipid Rafts
Saito, Y., Matsushima, T., & Suzuki, T. (2013) · InTech eBooks · doi:10.5772/54096 · Cited by 4 · cited 1×
“Nevertheless, A (cid:2) PP offers the flexibility of having multiple sites undergoing post-translational modifi-cations that could be exploited as a tool to selectively affect a putative A (cid:2) PP-dependent toxicity of A (cid:2) and tau oligomers [218].”
Morley (2010) · doi:10.3233/jad-2009-1230
Cited by
Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report
Nelson, P. T., Dickson, D. W., Trojanowski, J. Q., Jack, C. R., Boyle, P. A., Arfanakis, K., Rademakers, R., Alafuzoff, I., Attems, J., Brayne, C., et al. (2019) · Brain · doi:10.1093/brain/awz099 · Cited by 1,547
“Research into Alzheimer’s disease has provided additional topical caveats (Gulisano et al., 2018; Hunter et al., 2018; Morris et al., 2018).”
BackgroundZhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547
Gadhave, D. G., Sugandhi, V. V., Jha, S. K., Nangare, S. N., Gupta, G., Singh, S. K., Dua, K., Cho, H., Hansbro, P. M., & Paudel, K. R. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102357 · Cited by 358
“3 B) (Gulisano et al., 2018).”
Zhang, W., Xu, C., Sun, J., Shen, H.-M., Wang, J., & Yang, C. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.01.008 · Cited by 205
Metadata
- Authors
- Gulisano, W., Maugeri, D., Baltrons, M. A., Fà, M., Amato, A., Palmeri, A., D’Adamio, L., Grassi, C., Devanand, D. P., Honig, L. S., Puzzo, D., & Arancio, O.
- Affiliations
- University of Catania (IT)
- Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University, New York, NY, USA
- Columbia University (US)
- Università Cattolica del Sacro Cuore (IT)
- Department of Pharmacology, Physiology and Neuroscience, Rutgers University, Newark, NJ, USA
- Corresponding author
- Puzzo, Daniela
- Arancio, Ottavio
- ORCID
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2018-06-12
- Volume
- 64
- Issue
- s1
- Pages
- S611-S631
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC8371153
- OpenAlex
- W2807540667
- Cited by
- 313
- References
- 223
- Citations by year
- 2026: 59 · 2025: 92 · 2024: 60 · 2023: 32 · 2022: 23 · 2021: 17 · 2020: 18 · 2019: 10 · 2018: 2
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, public-domain)
- Funders
- National Institute on Aging (R01AG049402, R01AG017761)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta
- MeSH terms
- Alzheimer Disease, Animals, Humans, Signal Transduction, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.